Search

Displaying results 981 - 990 of 4344 in total
  1. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    The usage of glaucoma by pilocarpine dates back to 1875.[A262041] … [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.

  2. Drug

    Dicloxacillin

    go.drugbank.com/drugs/DB00485
    ApprovedInvestigationalVet approved

    One of the penicillins which is resistant to penicillinase.

  3. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]

  4. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.

  5. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]

  6. Drug

    Linaclotide

    go.drugbank.com/drugs/DB08890
    ApprovedInvestigational

    Linaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.

  7. Drug

    Radium Ra 223 dichloride

    go.drugbank.com/drugs/DB08913
    ApprovedInvestigational

    Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. … It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin.

  8. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [A224604] The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.

  9. Drug

    Chloramphenicol

    go.drugbank.com/drugs/DB00446
    ApprovedInvestigationalVet approvedWithdrawn

    An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. … It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic.

    Products: Pentamycetin Ont 10mg/gm
  10. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021,A262026,A262031] On November 17th, 2023, capivasertib, under the brand name TRUQAP, was approved by the FDA for the treatment of adult patients HR-positive, HER2-negative locally advanced or